Viral vector-based therapeutic cancer vaccines

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 359-371

  Larocca, Cecilia ^a,b   Schlom, Jeffrey ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

adenovirus; Cancer vaccines; immunotherapy; MVA vaccines; poxvirus vaccines; prime boost vaccination; TRICOM vaccines; viral vaccines

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHAVIRUS VECTOR; AVX 701; CANARYPOX VIRUS VECTOR; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; FOWLPOX VIRUS VECTOR; HERPES SIMPLEX VIRUS VECTOR; HERPESVIRUS VECTOR; IMMUNOSTIMULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEASLES VIRUS VECTOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MODIFIED VACCINIA VIRUS ANKARA VECTOR; MUCIN 1; PANVAC; PROSTATE SPECIFIC ANTIGEN; PROSTAVAC; SUNITINIB; T LYMPHOCYTE COSTIMULATORY MOLECULE B7.1; TG 4010; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS VECTOR; VESICULAR STOMATITIS VIRUS VECTOR; VIRUS VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MEGADOSE; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; IMMUNE RESPONSE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MULTICENTER STUDY (TOPIC); NEOPLASM; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSGENE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; MALE; PROSTATIC NEOPLASMS; VIRAL VACCINES; VIRUSES;

EID: 80053378780     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182325e63     Document Type: Review

References (101)

1. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. 1996;93: 11341-11348. (Pubitemid 26347123)
2. Brown M, Davies DH, Skinner MA, et al. Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Cancer Gene Ther. 1999;6:238-245. (Pubitemid 129667795)
3. Drillien R, Spehner D, Bohbot A, et al. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology. 2000;268:471-481. (Pubitemid 30159996)
4. Bonini C, Lee SP, Riddell SR, et al. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol. 2001;166:5250-5257. (Pubitemid 32280742)
5. Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunol. 2005;174:5994-6004. (Pubitemid 40663786)
6. Yang S, Tsang KY, Schlom J. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res. 2005;11:5603-5615. (Pubitemid 41060839)
7. Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst. 1992;84:1084-1091.
8. Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEAvirus. Cancer Res. 1999;59:676-683. (Pubitemid 29076067)
9. Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2007;13:5847-5854. (Pubitemid 47583910)
10. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm. 2011;8:12-28.
11. Myers R, Greiner S, Harvey M, et al. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005;12:593-599. (Pubitemid 40967219)
12. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol. 2009;330:213-241.
13. Lou E. Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncol. 2003;42:660-671. (Pubitemid 37445287)
14. Bridle BW, Boudreau JE, Lichty BD, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther. 2009;17:1814-1821.
15. Galanis E. Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther. 2010;88:620-625.
16. Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines. 2010;9:1275-1302.
17. Fenner F, Henderson D, Arita I. Smallpox and Its Eradication. Geneva: World Health Organization; 1988.
18. Jacobs BL, Langland JO, Kibler KV, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009;84:1-13.
19. Afonso CL, Tulman ER, Lu Z, et al. The genome of fowlpox virus. J Virol. 2000;74:3815-3831. (Pubitemid 30180324)
20. Tulman ER, Afonso CL, Lu Z, et al. The genome of canarypox virus. J Virol. 2004;78:353-366. (Pubitemid 37553163)
21. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J metastases Natl Cancer Inst. 1995;87:982-990.
22. Roberts KL, Smith GL. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 2008;16:472-479.
23. Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology. 1993;197:439-444.
24. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a selfantigen and antitumor activity. Cancer Res. 2002;62:5770-5777. (Pubitemid 35204734)
25. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord. 2003;3:263-271. (Pubitemid 37139046)
26. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis. 2003;26:343-355. (Pubitemid 37168472)
27. Kundig TM, Kalberer CP, Hengartner H, et al. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine. 1993;11:1154-1158. (Pubitemid 23278440)
28. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine. 1988;6:466-468. (Pubitemid 19001996)
29. Morse MA, Hobeika AC, Osada T, et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest. 2010;120:3234-3241.
30. Schlesinger S. Alphavirus vectors: development and potential therapeutic applications. Expert Opin Biol Ther. 2001;1:177-191. (Pubitemid 33770075)
31. Kelly BJ, Fleeton MN, Atkins GJ. Potential of alphavirus vectors in the treatment of advanced solid tumors. Recent Pat Anticancer Drug Discov. 2007;2:159-166. (Pubitemid 46952432)
32. Quetglas JI, Ruiz-Guillen M, Aranda A, et al. Alphavirus vectors for cancer therapy. Virus Res. 2010;153:179-196.
33. Dharmapuri S, Peruzzi D, Aurisicchio L. Engineered adenovirus serotypes for overcoming anti-vector immunity. Expert Opin Biol Ther. 2009;9:1279-1287.
34. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol. 2005;32:549-555. (Pubitemid 41772682)
35. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000;6:1632-1638. (Pubitemid 30305054)
36. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000;18:3964-3973.
37. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007;178:1515-1520. (Pubitemid 47368382)
38. Grosenbach DW, Feldman J, Schlom J, et al. Recombinant viral and bacterial vaccines. In: Kaufman H, Wolchok JD, eds. General Principles of Tumor Immunotherapy: Basic and CLinical Applications of Tumor Immunology. The Netherlands: Springer; 2008:217-250.
39. Kaufman HL, Wang W, Manola J, et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clincial results from ECOG 7897. J Clin Oncol. 23:16 (suppl), abstr 4501. 2005 ASCO Annual Meeting.
40. Kaufman HL, Cohen S, Cheung K, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 2006;17:239-244. (Pubitemid 43263093)
41. Palena C, Zhu M, Schlom J, et al. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood. 2004;104: 192-199. (Pubitemid 38879857)
42. Litzinger MT, Foon KA, Sabzevari H, et al. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients. Cancer Immunol Immunother. 2009;58:955-965.
43. Oh S, Hodge JW, Ahlers JD, et al. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol. 2003;170:2523-2530. (Pubitemid 36245642)
44. Lyerly HK, Hobeika A, Niedzwiecki D, et al. A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. J Clin Oncol. 2011;29(suppl), abstr 2533. 2011 ASCO Annual Meeting.
45. Morse M, Niedzwiecki D, Marshall J, et al. Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. J Clin Oncol. 2011;29(suppl) abstr 3557. 2011 ASCOAnnual Meeting.
46. Kass E, Panicali DL, Mazzara G, et al. Granulocyte/macrophagecolony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. 2001;61:206-214. (Pubitemid 32095719)
47. Reali E, Canter D, Zeytin H, et al. Comparative studies of Avipox-GMCSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine. 2005;23:2909-2921. (Pubitemid 40386493)
48. Kudo-Saito C, Garnett CT, Wansley EK, et al. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunol Immunother. 2007;56:1897-1910. (Pubitemid 47512611)
49. Kudo-Saito C, Wansley EK, Gruys ME, et al. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vectormediated costimulation and systemic interleukin-2. Clin Cancer Res. 2007;13:1936-1946. (Pubitemid 46957365)
50. Perera LP, Waldmann TA, Mosca JD, et al. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol. 2007;81: 8774-8783. (Pubitemid 47242850)
51. Liu L, Wang S, Shan B, et al. Advances in viral-vector systemic cytokine gene therapy against cancer. Vaccine. 2010;28:3883-3887.
52. Heery CR, Pinto PA, Schlom J, et al. Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. JClinOncol. 2011;29(suppl), abstr 2530. 2011 ASCOAnnual Meeting.
53. Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother. 2009;32:424-429.
54. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother. 2009;32: 765-772.
55. Kaufman HL, Taback B, Sherman W, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (Published online 2009 January 7. doi: 10.1186/1479-5876-7-2). J Transl Med. 2009:7.
56. Amato RJ, Shingler W, Naylor S, et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res. 2008;14:7504-7510.
57. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients withMVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010;16:5539-5547.
58. Oudard S, Rixe O, Beuselinck B, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother. 2011;60:261-271.
59. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12:3416-3424.
60. Elkord E, Dangoor A, Drury NL, et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother. 2008;31:820-829.
61. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008;57:977-986.
62. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13:4487-4494. (Pubitemid 47219718)
63. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother. 2008;31:577-585.
64. Dreicer R, Stadler WM, Ahmann FR, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009;27: 379-386.
65. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva- Muc1-Il2) in association with chemotherapy in patients with stage III/ IV Non-small cell lung cancer. J Thorac Oncol. 2008;3:735-744.
66. Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother. 2000;23:570-580.
67. Zajac P, Oertli D, Marti W, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumorassociated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther. 2003;14:1497-1510. (Pubitemid 37357738)
68. Spaner DE, Astsaturov I, Vogel T, et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer. 2006;106:890-899. (Pubitemid 43238457)
69. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2001;7:1181-1191. (Pubitemid 32708668)
70. Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008;14:4843-4849.
71. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res. 2000;6:2219-2228. (Pubitemid 30399187)
72. Lindsey KR, Gritz L, Sherry R, et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin Cancer Res. 2006;12:2526-2537.
73. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgenindependent prostate cancer. Clin Cancer Res. 2006;12:1260-1269. (Pubitemid 43342517)
74. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11:3353-3362. (Pubitemid 40627887)
75. Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol. 2005;174:539-546. (Pubitemid 40981596)
76. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res. 2008;14:4526-4531.
77. DiPaola RS, Chen Y, Bubley GJ, et al. A Phase II study of PROSTVACV (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802, abstr 108. 2009 ASCO Genitourinary Cancers Symposium.
78. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663-674.
79. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
80. Bilusic M, Gulley J, Heery C, et al. A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castrationresistant prostate cancer. J Clin Oncol. 2011;(suppl 7), abstr 163. 2011 ASCO Genitourinary Cancer Symposium.
81. Madan RA, Mohebtash M, Arlen PM, et al. Overall survival analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab in the treatment of metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:15s (suppl) abstr 2550. 2010 ASCO Annual Meeting.
82. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocytemacrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005;23:720-731. (Pubitemid 46224171)
83. Mohebtash M, Madan RA, Gulley JL, et al. PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer. J Clin Oncol. 2008;26(May 20 suppl), abstr 3035. 2008 ASCO Annual Meeting.
84. Therion Biologics Announces Conclusion of PANVAC-VF Phase 3 Trial. 2006. Available at: www.medicalnewstoday.com/medicalnews. php?newsid=46137. Accessed May 11, 2011.
85. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOMpoxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14:3060-3069.
86. NationalCancer Institute Clinical Trials (PDQ).Accessed:October 2007. Available at: www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 389439&version=HealthProfessional&protocolsearchid=2897251.
87. Anderson P, Nunez R. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther. 2007;7:1517-1527. (Pubitemid 350303011)
88. 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer. Available at: www. clinicaltrials.gov/ct2/ show/NCT00450619?term=Samarium+vaccine&rank=1. Accessed April 11, 2011.
89. Docetaxel alone or in combination with vaccine to treat breast cancer. Available at: www.clinicaltrials.gov/ct2/show/NCT00179309?term=gulley&rank= 9. Accessed April 11, 2011.
90. Petrylak D. Defining the optimal role of immunotherapy and chemotherapy: Advanced prostate cancer patients who receive sipuleucel-T (PROVENGE) followed by docetaxel derive greatest survival benefit. 14th Annual Meeting of the Chemotherapy Foundation Symposium. New York, NY. November. 8-11, 2006.
91. Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005;11:4430-4436. (Pubitemid 40825633)
92. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12:878-887. (Pubitemid 43259871)
93. Arlen PM, Pazdur M, Skarupa L, et al. A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer. 2006;7:176-179. (Pubitemid 44044019)
94. Docetaxel and prednisone with or without vaccine therapy in treating patients with metastatic hormone-resistant prostate cancer. Available at: www.clinicaltrials.gov/ct2/show/NCT01145508?term=McNeel&rank=5. Accessed April 11, 2011.
95. Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther. 2007;7:543-554. (Pubitemid 46524678)
96. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase IIIstudy from the German CONKO-study group. Eur J Cancer. 2011; 47:1676-1681.
97. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766. (Pubitemid 34547293)
98. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-722, discussion 722, 714.
99. Andres A, Majno PE, Morel P, et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol. 2008;15:134-143.
100. Arru M, Aldrighetti L, Castoldi R, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2008;32:93-103. (Pubitemid 50004245)
101. House MG, Ito H, Gonen M, et al. Survival after hepatic resection formetastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744-752.